Novo Nordisk A/S

$66.45
(as of Apr 30, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Novo Nordisk A/S

Stock Price
$66.45
Ticker Symbol
NVO
Exchange
NYSE

Industry Information for Novo Nordisk A/S

Sector
Healthcare
Industry
Drug Manufacturers - General

Company Description for Novo Nordisk A/S

Country
USA
Full Time Employees
76,302

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Fundamentals for Novo Nordisk A/S

Market Capitalization
$278,567,583,744
EBITDA
$146,668,994,560
Dividends per Share
$11.40
P/E Ratio
18.26
Forward P/E Ratio
15.02
Earnings per Share
$3.43
Earnings per Share Estimate Next Year
Profit Margin
34.78%
Shares Outstanding
3,364,179,968
Percent Owned by Insiders
0.00%
Percent Owned by Institutions
10.27%
52-Week High
52-Week Low

Technical Indicators for Novo Nordisk A/S

50-Day Moving Average
200-Day Moving Average
RSI
50.74
2.66

Analyst Ratings for Novo Nordisk A/S

Strong Buy
4
Buy
2
Hold
4
Sell
1
Strong Sell
1

News About Novo Nordisk A/S

May 1, 2025, 8:54 AM EST
Eli Lilly (LLY) reported first quarter earnings beating Wall Street's expectations Thursday on the top and bottom lines, but GLP-1 sales weren't as strong as expected. See more.
May 1, 2025, 6:30 AM EST
CVS (CVS) reported first quarter earnings Thursday, beating Wall Street's expectations. See more.
Apr 30, 2025, 4:48 PM EST
Medical pioneers Hims & Hers Health HIMS and Novo Nordisk NVO are making headlines this week after announcing a partnership to expand obesity care in the telehealth space. See more.
Apr 30, 2025, 7:20 AM EST
Humana (HUM) reported first quarter earnings that topped Wall Street expectations Wednesday, helping drive shares 5% higher in premarket trading. See more.